Abstract

MET Exon 14 Skipping Mutations: Essential Considerations for Current Management of Non–Small-Cell Lung Cancer

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
159P Clinical characteristics of patients with advanced NSCLC and MET exon 14 (METex14) skipping: A systematic literature review
A Gezin ... A Garcia
Journal of Thoracic Oncology | VOL. 16
A Gezin, et. al.A Gezin ... A Garcia
27 Mar 2021
The molecular and immune characteristics, antitumor activity of crizotinib in non-small cell lung cancer (NSCLC) patients with MET exon 14 skipping alterations.
Jiadi Gan ... Weineng Feng
Journal of Clinical Oncology | VOL. 37
Jiadi Gan, et. al.Jiadi Gan ... Weineng Feng
20 May 2019
Targeting MET Exon 14 Skipping Alterations: Has Lung Cancer MET Its Match?
Sanjay Popat ... Timothy A Yap
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | VOL. 12
Sanjay Popat, et. al.Sanjay Popat ... Timothy A Yap
01 Jan 2017
Targeted DNA- and RNA-based next-generation sequencing for identifying MET exon 14 alterations in pulmonary sarcomatoid carcinoma.
Junling Li ... Yan Li
Journal of Clinical Oncology | VOL. 35
Junling Li, et. al.Junling Li ... Yan Li
20 May 2017
View more papers

More From: The Journal of Molecular Diagnostics

Paper Title
Journal
Date
Author
Table of Contents
-
The Journal of Molecular Diagnostics | VOL. -
--
01 Jun 2024
Editorial Board
-
The Journal of Molecular Diagnostics | VOL. -
--
01 Jun 2024
Editorial Board
-
The Journal of Molecular Diagnostics | VOL. 26
--
01 May 2024
Table of Contents
-
The Journal of Molecular Diagnostics | VOL. 26
--
01 May 2024
View more papers